{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:46:48Z","timestamp":1778856408109,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mass spectrometry (MS) is emerging as a transformative diagnostic tool for plasma cell disorders, including multiple myeloma, Waldenstr\u00f6m macroglobulinemia, and light chain amyloidosis. Traditional diagnostic methods such as serum protein electrophoresis, immunofixation electrophoresis, and serum free light chain assays, though effective, have limitations in sensitivity and specificity. These techniques may miss small monoclonal proteins or be affected by therapeutic antibody interference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>Recent advances focus on top-down MS techniques, particularly matrix-assisted laser desorption\/ionization time-of-flight (MALDI-TOF) and monoclonal immunoglobulin rapid accurate mass measurement (miRAMM). These methods analyze intact monoclonal proteins to enhance detection sensitivity and specificity. MALDI-TOF offers a streamlined workflow suitable for clinical laboratories, while miRAMM provides highly precise mass measurements, albeit requiring more sophisticated instrumentation.<\/jats:p>\n                    <jats:p>MS has demonstrated superior capabilities in detecting monoclonal proteins, including the ability to distinguish them from therapeutic antibodies. Additionally, MS enables structural characterization of monoclonal proteins, such as glycosylation patterns linked to amyloidosis. Notably, emerging evidence indicates that MS may match or surpass the sensitivity of molecular techniques. These include next-generation sequencing and next-generation flow cytometry, which are commonly applied to bone marrow biopsy for minimal residual disease detection, providing a less invasive alternative for disease monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>MS, particularly MALDI-TOF and miRAMM, represents a promising advancement in the diagnosis and monitoring of plasma cell disorders. Its high sensitivity, efficiency, and noninvasive nature support its potential to complement or replace existing diagnostic methods, improving patient care and clinical outcomes as the technology continues to evolve.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfaf133","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:55:56Z","timestamp":1755777356000},"page":"1658-1663","source":"Crossref","is-referenced-by-count":3,"title":["The Transformative Role of Mass Spectrometry in Diagnosing and Monitoring Monoclonal Gammopathies and Plasma Cell Disorders"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0976-2653","authenticated-orcid":false,"given":"Gema","family":"Garc\u00eda de la Rosa","sequence":"first","affiliation":[{"name":"Department of Clinical Analysis Laboratory, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"de las Heras Fl\u00f3rez","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis Laboratory, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Carretero P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis Laboratory, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Nuevo Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis Laboratory, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2025110423192993600_jfaf133-B1","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"2025110423192993600_jfaf133-B2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"2025110423192993600_jfaf133-B3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem"},{"key":"2025110423192993600_jfaf133-B4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1515\/cclm-2019-1104","article-title":"An international multicenter serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis","volume":"58","author":"Turner","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2025110423192993600_jfaf133-B5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ajcp\/aqy037","article-title":"Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of daratumumab and elotuzumab","volume":"150","author":"Tang","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"2025110423192993600_jfaf133-B6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025110423192993600_jfaf133-B7","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1021\/acs.jproteome.2c00265","article-title":"A comparative survey of bottom-up and top-down proteomics sample preparation methods highlights challenges in clinical workflows","volume":"21","author":"Varnavides","year":"2022","journal-title":"J Proteome Res"},{"key":"2025110423192993600_jfaf133-B8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J Proteome Res"},{"key":"2025110423192993600_jfaf133-B9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1515\/cclm-2020-0581","article-title":"Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab","volume":"59","author":"Kohlhagen","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2025110423192993600_jfaf133-B10","doi-asserted-by":"crossref","first-page":"1073479","DOI":"10.3389\/fonc.2022.1073479","article-title":"MALDI-TOF-MS for rapid screening analysis of M-protein in serum","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"2025110423192993600_jfaf133-B11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025110423192993600_jfaf133-B12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"key":"2025110423192993600_jfaf133-B13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinbiochem.2021.02.011","article-title":"Clearing drug interferences in myeloma treatment using mass spectrometry","volume":"92","author":"Kohlhagen","year":"2021","journal-title":"Clin Biochem"},{"key":"2025110423192993600_jfaf133-B14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","article-title":"A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference","volume":"132","author":"Mills","year":"2018","journal-title":"Blood"},{"key":"2025110423192993600_jfaf133-B15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1021\/acs.analchem.0c03357","article-title":"High-throughput therapeutic antibody interference-free high-resolution mass spectrometry assay for monitoring M-proteins in multiple myeloma","volume":"93","author":"Santockyte","year":"2021","journal-title":"Anal Chem"},{"key":"2025110423192993600_jfaf133-B16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41375-018-0194-x","article-title":"Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"key":"2025110423192993600_jfaf133-B17","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025110423192993600_jfaf133-B18","first-page":"582","article-title":"Minimal residual disease in multiple myeloma: why, when, where","volume":"2021","author":"Yee","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025110423192993600_jfaf133-B19","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"key":"2025110423192993600_jfaf133-B20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-023-00803-z","article-title":"Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025110423192993600_jfaf133-B21","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J Proteome Res"},{"key":"2025110423192993600_jfaf133-B22","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs. next-generation sequencing in bone marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/6\/1658\/64265231\/jfaf133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/6\/1658\/64265231\/jfaf133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:19:36Z","timestamp":1762316376000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/10\/6\/1658\/8253928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,15]]},"published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfaf133","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,15]]}}}